Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)

Frank L. Silver, Ariane Mackey, Wayne M. Clark, William Brooks, Carlos H. Timaran, David Chiu, Larry B. Goldstein, James F. Meschia, Robert D. Ferguson, Wesley S. Moore, George Howard, Thomas G. Brott

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE - The safety of carotid artery stenting (CAS) and carotid endarterectomy (CEA) has varied by symptomatic status in previous trials. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) data were analyzed to determine safety in symptomatic and asymptomatic patients. METHODS - CREST is a randomized trial comparing safety and efficacy of CAS versus CEA in patients with high-grade carotid stenoses. Patients were defined as symptomatic if they had relevant symptoms within 180 days of randomization. The primary end point was stroke, myocardial infarction, or death within the periprocedural period or ipsilateral stroke up to 4 years. RESULTS - For 1321 symptomatic and 1181 asymptomatic patients, the periprocedural aggregate of stroke, myocardial infarction, and death did not differ between CAS and CEA (5.2% versus 4.5%; hazard ratio, 1.18; 95% CI, 0.82 to 1.68; P=0.38). The stroke and death rate was higher for CAS versus CEA (4.4% versus 2.3%; hazard ratio, 1.90; 95% CI, 1.21 to 2.98; P=0.005). For symptomatic patients, the periprocedural stroke and death rates were 6.0%±0.9% for CAS and 3.2%±0.7% for CEA (hazard ratio, 1.89; 95% CI, 1.11 to 3.21; P=0.02). For asymptomatic patients, the stroke and death rates were 2.5%±0.6% for CAS and 1.4%±0.5% for CEA (hazard ratio, 1.88; 95% CI, 0.79 to 4.42; P=0.15). Rates were lower for those aged <80 years. CONCLUSIONS - There were no significant differences between CAS versus CEA by symptomatic status for the primary CREST end point. Periprocedural stroke and death rates were significantly lower for CEA in symptomatic patients. However, for both CAS and CEA, stroke and death rates were below or comparable to those of previous randomized trials and were within the complication thresholds suggested in current guidelines for both symptomatic and asymptomatic patients.

Original languageEnglish (US)
Pages (from-to)675-680
Number of pages6
JournalStroke
Volume42
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Endarterectomy
Carotid Endarterectomy
Carotid Arteries
Safety
Stroke
Mortality
Myocardial Infarction
Carotid Stenosis
Random Allocation

Keywords

  • carotid endarterectomy
  • cerebral infarct
  • cerebrovascular disease
  • clinical trials
  • myocardial infarction
  • stenting
  • surgery/endarterectomy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). / Silver, Frank L.; Mackey, Ariane; Clark, Wayne M.; Brooks, William; Timaran, Carlos H.; Chiu, David; Goldstein, Larry B.; Meschia, James F.; Ferguson, Robert D.; Moore, Wesley S.; Howard, George; Brott, Thomas G.

In: Stroke, Vol. 42, No. 3, 03.2011, p. 675-680.

Research output: Contribution to journalArticle

Silver, FL, Mackey, A, Clark, WM, Brooks, W, Timaran, CH, Chiu, D, Goldstein, LB, Meschia, JF, Ferguson, RD, Moore, WS, Howard, G & Brott, TG 2011, 'Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)', Stroke, vol. 42, no. 3, pp. 675-680. https://doi.org/10.1161/STROKEAHA.110.610212
Silver, Frank L. ; Mackey, Ariane ; Clark, Wayne M. ; Brooks, William ; Timaran, Carlos H. ; Chiu, David ; Goldstein, Larry B. ; Meschia, James F. ; Ferguson, Robert D. ; Moore, Wesley S. ; Howard, George ; Brott, Thomas G. / Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). In: Stroke. 2011 ; Vol. 42, No. 3. pp. 675-680.
@article{e6a45c27d7b34f52a97fc15f869eb792,
title = "Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)",
abstract = "BACKGROUND AND PURPOSE - The safety of carotid artery stenting (CAS) and carotid endarterectomy (CEA) has varied by symptomatic status in previous trials. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) data were analyzed to determine safety in symptomatic and asymptomatic patients. METHODS - CREST is a randomized trial comparing safety and efficacy of CAS versus CEA in patients with high-grade carotid stenoses. Patients were defined as symptomatic if they had relevant symptoms within 180 days of randomization. The primary end point was stroke, myocardial infarction, or death within the periprocedural period or ipsilateral stroke up to 4 years. RESULTS - For 1321 symptomatic and 1181 asymptomatic patients, the periprocedural aggregate of stroke, myocardial infarction, and death did not differ between CAS and CEA (5.2{\%} versus 4.5{\%}; hazard ratio, 1.18; 95{\%} CI, 0.82 to 1.68; P=0.38). The stroke and death rate was higher for CAS versus CEA (4.4{\%} versus 2.3{\%}; hazard ratio, 1.90; 95{\%} CI, 1.21 to 2.98; P=0.005). For symptomatic patients, the periprocedural stroke and death rates were 6.0{\%}±0.9{\%} for CAS and 3.2{\%}±0.7{\%} for CEA (hazard ratio, 1.89; 95{\%} CI, 1.11 to 3.21; P=0.02). For asymptomatic patients, the stroke and death rates were 2.5{\%}±0.6{\%} for CAS and 1.4{\%}±0.5{\%} for CEA (hazard ratio, 1.88; 95{\%} CI, 0.79 to 4.42; P=0.15). Rates were lower for those aged <80 years. CONCLUSIONS - There were no significant differences between CAS versus CEA by symptomatic status for the primary CREST end point. Periprocedural stroke and death rates were significantly lower for CEA in symptomatic patients. However, for both CAS and CEA, stroke and death rates were below or comparable to those of previous randomized trials and were within the complication thresholds suggested in current guidelines for both symptomatic and asymptomatic patients.",
keywords = "carotid endarterectomy, cerebral infarct, cerebrovascular disease, clinical trials, myocardial infarction, stenting, surgery/endarterectomy",
author = "Silver, {Frank L.} and Ariane Mackey and Clark, {Wayne M.} and William Brooks and Timaran, {Carlos H.} and David Chiu and Goldstein, {Larry B.} and Meschia, {James F.} and Ferguson, {Robert D.} and Moore, {Wesley S.} and George Howard and Brott, {Thomas G.}",
year = "2011",
month = "3",
doi = "10.1161/STROKEAHA.110.610212",
language = "English (US)",
volume = "42",
pages = "675--680",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)

AU - Silver, Frank L.

AU - Mackey, Ariane

AU - Clark, Wayne M.

AU - Brooks, William

AU - Timaran, Carlos H.

AU - Chiu, David

AU - Goldstein, Larry B.

AU - Meschia, James F.

AU - Ferguson, Robert D.

AU - Moore, Wesley S.

AU - Howard, George

AU - Brott, Thomas G.

PY - 2011/3

Y1 - 2011/3

N2 - BACKGROUND AND PURPOSE - The safety of carotid artery stenting (CAS) and carotid endarterectomy (CEA) has varied by symptomatic status in previous trials. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) data were analyzed to determine safety in symptomatic and asymptomatic patients. METHODS - CREST is a randomized trial comparing safety and efficacy of CAS versus CEA in patients with high-grade carotid stenoses. Patients were defined as symptomatic if they had relevant symptoms within 180 days of randomization. The primary end point was stroke, myocardial infarction, or death within the periprocedural period or ipsilateral stroke up to 4 years. RESULTS - For 1321 symptomatic and 1181 asymptomatic patients, the periprocedural aggregate of stroke, myocardial infarction, and death did not differ between CAS and CEA (5.2% versus 4.5%; hazard ratio, 1.18; 95% CI, 0.82 to 1.68; P=0.38). The stroke and death rate was higher for CAS versus CEA (4.4% versus 2.3%; hazard ratio, 1.90; 95% CI, 1.21 to 2.98; P=0.005). For symptomatic patients, the periprocedural stroke and death rates were 6.0%±0.9% for CAS and 3.2%±0.7% for CEA (hazard ratio, 1.89; 95% CI, 1.11 to 3.21; P=0.02). For asymptomatic patients, the stroke and death rates were 2.5%±0.6% for CAS and 1.4%±0.5% for CEA (hazard ratio, 1.88; 95% CI, 0.79 to 4.42; P=0.15). Rates were lower for those aged <80 years. CONCLUSIONS - There were no significant differences between CAS versus CEA by symptomatic status for the primary CREST end point. Periprocedural stroke and death rates were significantly lower for CEA in symptomatic patients. However, for both CAS and CEA, stroke and death rates were below or comparable to those of previous randomized trials and were within the complication thresholds suggested in current guidelines for both symptomatic and asymptomatic patients.

AB - BACKGROUND AND PURPOSE - The safety of carotid artery stenting (CAS) and carotid endarterectomy (CEA) has varied by symptomatic status in previous trials. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) data were analyzed to determine safety in symptomatic and asymptomatic patients. METHODS - CREST is a randomized trial comparing safety and efficacy of CAS versus CEA in patients with high-grade carotid stenoses. Patients were defined as symptomatic if they had relevant symptoms within 180 days of randomization. The primary end point was stroke, myocardial infarction, or death within the periprocedural period or ipsilateral stroke up to 4 years. RESULTS - For 1321 symptomatic and 1181 asymptomatic patients, the periprocedural aggregate of stroke, myocardial infarction, and death did not differ between CAS and CEA (5.2% versus 4.5%; hazard ratio, 1.18; 95% CI, 0.82 to 1.68; P=0.38). The stroke and death rate was higher for CAS versus CEA (4.4% versus 2.3%; hazard ratio, 1.90; 95% CI, 1.21 to 2.98; P=0.005). For symptomatic patients, the periprocedural stroke and death rates were 6.0%±0.9% for CAS and 3.2%±0.7% for CEA (hazard ratio, 1.89; 95% CI, 1.11 to 3.21; P=0.02). For asymptomatic patients, the stroke and death rates were 2.5%±0.6% for CAS and 1.4%±0.5% for CEA (hazard ratio, 1.88; 95% CI, 0.79 to 4.42; P=0.15). Rates were lower for those aged <80 years. CONCLUSIONS - There were no significant differences between CAS versus CEA by symptomatic status for the primary CREST end point. Periprocedural stroke and death rates were significantly lower for CEA in symptomatic patients. However, for both CAS and CEA, stroke and death rates were below or comparable to those of previous randomized trials and were within the complication thresholds suggested in current guidelines for both symptomatic and asymptomatic patients.

KW - carotid endarterectomy

KW - cerebral infarct

KW - cerebrovascular disease

KW - clinical trials

KW - myocardial infarction

KW - stenting

KW - surgery/endarterectomy

UR - http://www.scopus.com/inward/record.url?scp=79952067678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952067678&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.110.610212

DO - 10.1161/STROKEAHA.110.610212

M3 - Article

VL - 42

SP - 675

EP - 680

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 3

ER -